医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial

2022年08月03日 PM11:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

ImmunAbs Inc. (www.immunabs.com) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States.

ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, when out of regulation, cause various autoimmune diseases, including but not limited to paroxysmal nocturnal hemoglobinuria (PNH). The complement inhibitors drug market showed its growth potential by achieving an average annual growth rate of 20.7% and a market size of USD $ 5.1 billion in 2020 and is expected to grow to USD $19 billion by 2027.

Paroxysmal nocturnal hemoglobinuria is one example of complement-mediated autoimmune diseases where the membrane proteins protecting the red blood cells from complement activation are lost due to mutations, which results in red blood cells being destructed by the complements. Due to insufficient inhibition of complements shown by currently approved complement inhibitors, Soliris and Ultomiris, patients who receive these drugs still suffer from the residual symptoms of PNH, which include anaemia, fatigue, and decreased productivity at work.

ImmunAbs’ new complement therapeutic IM-101 targets the safest and most potent component of the complement system, complement C5. IM-101 has been shown to completely inhibit complement activation, and thus is expected to alleviate the symptoms that persist with the standard of care. ImmunAbs will initiate a phase 2a clinical trial in the United States in 2024.

“This is a historical milestone for ImmunAbs.” said Dr. DongJo Kim, the company’s CEO. “We are delighted to see IM-101’s efficacy in humans which has been proven in our ex vivo study. We hope that our IM-101 will reach patients who may suffer from symptoms that persist due to insufficient complement inhibition by the current treatments.”

About ImmunAbs Inc.

ImmunAbs Inc. was established in 2017 by experts of global standard antibody therapeutics development. The vision is “Hope for Patients, Dreams for All.” Currently, ImmunAbs has several antibody therapeutics in global standard development for autoimmune diseases, diabetic retinopathy, and metabolic syndrome. ImmunAbs successfully raised KRW 18.1 billion from Seed to series A funding in 2021 and got a non-clinical study national grant for developing IM-101 from Korea Drug Development Fund in November last year.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005380/en/

CONTACT

HyunJung Jung

Business Development Manager

Hyunjung.Jung@ImmunAbs.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer
  • Aurion Biotech Nominated for Prix Galien Startup Award
  • ICS Cybersecurity Leader TXOne Networks Raises $70 Million in Series B Funding
  • Publication in Nature Molecular Psychiatry Supports Genuv’s Alternate Theory for Treatment of Alzheimer’s Disease
  • Restore EF試験で、Impella補助による高リスクPCI患者の心機能および症状改善を確認